Condition overview
Ibogaine for addiction & opioid detox
In addiction contexts, IV ibogaine infusion means intravenous psychoactive delivery of ibogaine under physician supervision — sometimes explored for interrupting opioid withdrawal. Interest is real. Proof of a universal, regulator-approved cure is not. Cardiac risk and aftercare remain central.
Programs discussed on this site for physician-supervised IV ibogaine infusion are provisionally available in Mexico — not an FDA-approved U.S. clinic treatment. Educational only; not legal advice.
Honest bottom line
Some open-label and observational reports — predominantly oral-route — describe meaningful short-term reductions in withdrawal severity or opioid use for some participants. That is not a proven, FDA-approved treatment for opioid use disorder (OUD), and it is not automatic proof that a psychoactive IV protocol will match those outcomes.
Systematic reviews repeatedly conclude that therapeutic signals are intriguing but constrained by small samples, bias risk, heterogeneous methods, and cardiac safety concerns.
Why opioids dominate the conversation
Historical clinical and underground interest focused on opioid withdrawal interruption. Ibogaine’s complex pharmacology — including effects relevant to opioid pathways and its metabolite noribogaine — led researchers to study craving and withdrawal outcomes.
Hope statements you will see online (which we will not turn into guarantees):
- Shorter acute withdrawal window than unaided detox
- Reduced craving for a period after the session
- A psychologically motivating “reset” for recovery work
Even when withdrawal relief is reported, addiction is a chronic, relapsing condition. Medical detox interruption ≠ long-term recovery without psychosocial care, overdose prevention planning, and often ongoing evidence-based treatment (including MOUD when appropriate).
What the evidence can and cannot say
Observational signals (mostly oral)
Cardiac-focused observational work (e.g., Knuijver et al., Addiction, 2021) documented clinically relevant QTc prolongation after oral ibogaine HCl in opioid-dependent patients — reinforcing that anti-withdrawal interest and cardiac risk travel together.
IV psychoactive evidence gap
Peer-reviewed controlled trials of psychoactive IV ibogaine infusion are not established like oral observational series. Brand positioning as IV infusion must not launder oral study percentages into “IV success rates.”
Where medical IV care fits
- Withdrawal and polysubstance status change vital signs and electrolytes
- QTc risk requires continuous monitoring, not intermittent spot-checks
- Physician-supervised IV psychoactive infusion needs clear dosing/stop rules and emergency capability
- Support IV (fluids, Mg/K, antiemetics) may still be used — labeled separately
- Aftercare planning, including overdose risk if relapse occurs, is part of ethical care
How this differs from standard OUD tools
| Approach | Role (simplified) | Access / evidence posture |
|---|---|---|
| Methadone / buprenorphine (MOUD) | Evidence-based maintenance / treatment | Guideline-supported where available |
| Medical detox / symptomatic care | Stabilize withdrawal | Standard pathways; not a cure alone |
| IV ibogaine infusion (investigational interest) | Acute interrupt curiosity under medical monitoring | Not FDA-approved; sparse IV controlled data |
Risk themes specific to substance-use contexts
- Recent use patterns and polysubstance risk
- Medication interactions and QT-related concerns
- Dehydration, electrolytes, and physical frailty
- Post-acute vulnerability and overdose risk if tolerance changes after an interrupt
Next steps
Review safety & screening, read what infusion means, compare cost transparency on cost of treatment, then submit a confidential inquiry.
Next step
Inquire about addiction-focused screening
Screening comes before any treatment conversation — not after a sales pitch. Supervised IV ibogaine infusion inquiry is available provisionally in Mexico; not a U.S. FDA-approved clinic.